<PAGE>
Exhibit 23.1
INDEPENDENT ACCOUNTANTS' CONSENT
The Board of Directors
Cubist Pharmaceuticals Inc.
(formerly TerraGen Discovery Inc.)
We consent to the incorporation by reference in the registration statements
(Nos. 333-64943, 333-90137, 333-96365 and 333-32186) on Form S-3
and (Nos. 333-49522, 333-32178, 333-65385, 333-65383 and 333-25707) on Form
S-8 of Cubist Pharmaceuticals, Inc. (the "Company") of our report dated April
3, 2000, except as to note 1 which is as of December 7, 2000 and note 13
which is as of October 23, 2000 with respect to the consolidated balance
sheets of Cubist Pharmaceuticals, Inc. (formerly TerraGen Discovery Inc.) as
of December 31, 1999 and 1998, and the consolidated statements of operations,
stockholders' equity and comprehensive income and cash flows for each of the
years in the three-year period ended December 31, 1999, which report appears
in the Form 8-K of Cubist Pharmaceuticals, Inc.
Our report is dated April 3, 2000, except as to note 1 which is as of
December 7, 2000 and note 13 which is as of October 23, 2000 and refers to
the acquisition of Cubist Pharmaceuticals Inc. (formerly TerraGen Discovery
Inc.) by Cubist Pharmaceuticals, Inc., a United States incorporated public
company. Our report contains an explanatory paragraph that states that Cubist
Pharmaceuticals Inc. (formerly TerraGen Discovery Inc.) has suffered
recurring losses from operations and negative cash flows, which raise
substantial doubt about its ability to continue as a going concern. The
consolidated financial statements do not include any adjustments that might
result from the outcome of that uncertainty.
Chartered Accountants
/s/ KPMG LLP
Vancouver, Canada
January 8, 2001
